<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01006096</url>
  </required_header>
  <id_info>
    <org_study_id>MEL-041509</org_study_id>
    <nct_id>NCT01006096</nct_id>
  </id_info>
  <brief_title>Erlotinib for Treatment of Psoriasis</brief_title>
  <official_title>Phase II Randomized, Double-blind, Placebo-controlled, Two-arm Study to Evaluate the Safety and Efficacy of Erlotinib in the Treatment of Moderate to Severe Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>OSI Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether erlotinib is effective in the treatment of
      psoriasis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Psoriasis vulgaris is a disease that affects 25 million people in North America and Europe.
      It often presents in late adolescence and usually persists for life. Current therapies target
      specific immune molecules that are implicated in the cause of this disease. For example,
      biologic agents that are used in severe psoriasis are aimed at inflammatory mediators. These
      therapies have been proven to be effective but also have their limitations.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    IND not obtained
  </why_stopped>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine efficacy of erlotinib in treatment of moderate to severe psoriasis measured by the Psoriasis Area and Severity Index (PASI) and the Physician's Global Assessment (PGA).</measure>
    <time_frame>week 4, 8, 12, 16, and 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the rate of dose reduction or interruption as a result of adverse events.</measure>
    <time_frame>week 4, 8, 12, 16, and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine quality of life using the Dermatology Life Quality Index (DLQI).</measure>
    <time_frame>week 4, 8, 12, 16, and 24</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Erlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo tablets</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib</intervention_name>
    <description>100mg tablet, once daily for 16 weeks</description>
    <arm_group_label>Erlotinib</arm_group_label>
    <other_name>Tarceva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo tablet</intervention_name>
    <description>placebo tablet (lactose), once daily for 16 weeks</description>
    <arm_group_label>Placebo tablets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of moderate to severe psoriasis

          -  Must have documented moderate to severe psoriasis by the Physician's Global Assessment
             (PGA) and the Psoriasis Area Severity Index (PASI)

          -  Must be able to swallow tablets

          -  Must be able to provide written informed consent

          -  Subjects with reproductive potential (menopausal for less than 1 year and not
             surgically sterilized) must practice effective contraceptive measures throughout the
             study and thirty days after discontinuation of study drug. Women of childbearing
             potential must provide negative pregnancy test (serum or urine) within 14 days prior
             to randomization.

        Exclusion Criteria:

          -  Use of concurrent agents/therapies for psoriasis

          -  Bilirubin &gt; 3 X ≥ ULN or moderate to severe hepatic impairment

          -  Pregnant or breast-feeding females

          -  Subjects currently receiving other anticancer treatments

          -  Subjects currently receiving other biologic treatments

          -  Subjects currently receiving blood thinners (warfarin or heparin)

          -  Subjects who currently smoke

          -  Subjects with other skin disease which in the opinion of the investigator, would
             inhibit the ability to use the PGA and PASI evaluation methods
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne E Laumann, MBChB, MRCP (UK)</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University Feinberg School of Medicine Department of Dermatology</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature. 2007 Feb 22;445(7130):866-73. Review.</citation>
    <PMID>17314973</PMID>
  </reference>
  <reference>
    <citation>Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabárbara P, Seymour L; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005 Jul 14;353(2):123-32.</citation>
    <PMID>16014882</PMID>
  </reference>
  <reference>
    <citation>Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer. 2006 Oct;6(10):803-12. Review.</citation>
    <PMID>16990857</PMID>
  </reference>
  <reference>
    <citation>Wierzbicka E, Tourani JM, Guillet G. Improvement of psoriasis and cutaneous side-effects during tyrosine kinase inhibitor therapy for renal metastatic adenocarcinoma. A role for epidermal growth factor receptor (EGFR) inhibitors in psoriasis? Br J Dermatol. 2006 Jul;155(1):213-4.</citation>
    <PMID>16792781</PMID>
  </reference>
  <reference>
    <citation>Ben-Bassat H, Vardi DV, Gazit A, Klaus SN, Chaouat M, Hartzstark Z, Levitzki A. Tyrphostins suppress the growth of psoriatic keratinocytes. Exp Dermatol. 1995 Apr;4(2):82-8.</citation>
    <PMID>7640880</PMID>
  </reference>
  <reference>
    <citation>Powell TJ, Ben-Bassat H, Klein BY, Chen H, Shenoy N, McCollough J, Narog B, Gazit A, Harzstark Z, Chaouat M, Levitzki R, Tang C, McMahon J, Shawver L, Levitzki A. Growth inhibition of psoriatic keratinocytes by quinazoline tyrosine kinase inhibitors. Br J Dermatol. 1999 Nov;141(5):802-10.</citation>
    <PMID>10583160</PMID>
  </reference>
  <reference>
    <citation>Ben-Bassat H, Klein BY. Inhibitors of tyrosine kinases in the treatment of psoriasis. Curr Pharm Des. 2000 Jun;6(9):933-42. Review.</citation>
    <PMID>10828317</PMID>
  </reference>
  <reference>
    <citation>Ben-Bassat H, Levitzki A. Inhibitors of tyrosine kinases in the treatment of psoriasis. Isr Med Assoc J. 2000 Jul;2 Suppl:69-73. Review.</citation>
    <PMID>10909421</PMID>
  </reference>
  <reference>
    <citation>Halin C, Fahrngruber H, Meingassner JG, Bold G, Littlewood-Evans A, Stuetz A, Detmar M. Inhibition of chronic and acute skin inflammation by treatment with a vascular endothelial growth factor receptor tyrosine kinase inhibitor. Am J Pathol. 2008 Jul;173(1):265-77. doi: 10.2353/ajpath.2008.071074. Epub 2008 Jun 5.</citation>
    <PMID>18535184</PMID>
  </reference>
  <reference>
    <citation>Forsberg S, Ostman A, Rollman O. Regeneration of human epidermis on acellular dermis is impeded by small-molecule inhibitors of EGF receptor tyrosine kinase. Arch Dermatol Res. 2008 Oct;300(9):505-16. doi: 10.1007/s00403-008-0853-2. Epub 2008 Apr 30.</citation>
    <PMID>18446355</PMID>
  </reference>
  <reference>
    <citation>Neyns B, Meert V, Vandenbroucke F. Cetuximab treatment in a patient with metastatic colorectal cancer and psoriasis. Curr Oncol. 2008 Aug;15(4):196-7.</citation>
    <PMID>18769609</PMID>
  </reference>
  <reference>
    <citation>Trivin F, Boucher E, Raoul JL. Complete sustained regression of extensive psoriasis with cetuximab combination chemotherapy. Acta Oncol. 2004;43(6):592-3.</citation>
    <PMID>15370619</PMID>
  </reference>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 29, 2009</study_first_submitted>
  <study_first_submitted_qc>October 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2009</study_first_posted>
  <last_update_submitted>November 7, 2014</last_update_submitted>
  <last_update_submitted_qc>November 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 10, 2014</last_update_posted>
  <responsible_party>
    <name_title>Anne E. Laumann, MBChB, MRCP (UK)/Associate Professor</name_title>
    <organization>Northwestern University</organization>
  </responsible_party>
  <keyword>Psoriasis</keyword>
  <keyword>double-blind</keyword>
  <keyword>randomized</keyword>
  <keyword>placebo-controlled</keyword>
  <keyword>erlotinib</keyword>
  <keyword>efficacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

